PBS update: Lenalidomide maintenance and changes to bortezomib access due to COVID19

Lenalidomide (Revlimid®) maintenance post autologous stem cell transplant We are delighted to announce that as of 1 April 2020 the pharmaceutical benefits scheme (PBS) have listed lenalidomide (Revlim...

ASH conference 2019

Earlier this month, a team from Myeloma Australia visited Orlando, Florida in the USA for the annual American Society of Hematology (ASH) conference as invited guests of the International Myeloma Foun...

PBAC Meeting Nov: Daratumumab combination and Pomalidomide combination

A couple of weeks ago we sent out a special advocacy edition of the Muster to inform you of the latest submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for the upcoming November PB...